良性前列腺增生症是中老年男性中比较常见的一类排尿障碍类的疾病,主要临床表现是下尿路症状(LUTS),它包括尿等待、尿流不畅、排尿不全、尿潴留、尿失禁,以及刺激性症状尿频、尿急、夜尿和急迫性尿失禁等。它严重影响中老年的生活质量,现在主要的治疗方式是微创手术治疗、药物治疗。其中药物治疗是治疗前列腺增生不可或缺的一个部分,主要包括α受体阻滞剂、5-α还原酶抑制剂、M受体阻滞剂、磷酸二酯酶-5-抑制剂、β3激动剂、植物制剂、联合治疗及中医药。现在由于发病人群的年轻化以及病情的轻重程度使药物治疗逐渐成为了某些患者的首选治疗方式。
Benign prostatic hyperplasia (BPH) is a common urination disorder in middle-aged and elderly man. Its main clinical manifestation is lower urinary tract symptoms (LUTS), which include urinary wait-ing, dyspnea, dysuria, urinary retention, urinary incontinence, irritant symptoms such as frequent urination, urgent urination, nocturnal urination and urgent urinary incontinence. It seriously af-fects the quality of life of the middle-aged and elderly, and now the main treatment is minimally invasive surgery and drug therapy. Drug therapy is an indispensable part of the treatment of be-nign prostatic hyperplasia. It mainly includes α receptor blockers, 5-α reductase inhibitors, M re-ceptor blockers, phosphodiesterase-5-inhibitors, β3 agonists, plant preparations, combined therapy and traditional Chinese medicine. Now, due to the younger age of the disease and the severity of the disease, drug therapy has gradually become the first choice for some patients.
前列腺,良性前列腺增生,药物治疗, Prostate Benign Prostatic Hyperplasia Drug Therapy摘要
Benign prostatic hyperplasia (BPH) is a common urination disorder in middle-aged and elderly man. Its main clinical manifestation is lower urinary tract symptoms (LUTS), which include urinary waiting, dyspnea, dysuria, urinary retention, urinary incontinence, irritant symptoms such as frequent urination, urgent urination, nocturnal urination and urgent urinary incontinence. It seriously affects the quality of life of the middle-aged and elderly, and now the main treatment is minimally invasive surgery and drug therapy. Drug therapy is an indispensable part of the treatment of benign prostatic hyperplasia. It mainly includes α receptor blockers, 5-α reductase inhibitors, M receptor blockers, phosphodiesterase-5-inhibitors, β3 agonists, plant preparations, combined therapy and traditional Chinese medicine. Now, due to the younger age of the disease and the severity of the disease, drug therapy has gradually become the first choice for some patients.
Keywords:Prostate, Benign Prostatic Hyperplasia, Drug Therapy
陶俊东,张景欣. 良性前列腺增生的药物治疗现状Current Status of Drug Therapy for Benign Prostatic Hyperplasia[J]. 临床医学进展, 2022, 12(11): 10146-10151. https://doi.org/10.12677/ACM.2022.12111463
参考文献ReferencesZhang, X., Xiao, L., Zhang, L., et al. (2022) Associated Factors for Prostate Enlargement in Chinese Adult Men Aged <40 Receiving Checkups. International Journal of Clinical Practice, 2022, Article ID: 4792451.
<br>https://doi.org/10.1155/2022/4792451Egan, K.B. (2016) The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urologic Clinics of North America, 43, 289-297.
<br>https://doi.org/10.1016/j.ucl.2016.04.001Saito, M., Tsounapi, P., Oikawa, R., et al. (2014) Prostatic Ischemia Induces Ventral Prostatic Hyperplasia in the SHR; Possible Mechanism of Development of BPH. Scientific Reports, 4, Article No. 3822.
<br>https://doi.org/10.1038/srep03822Oelke, M., Gericke, A. and Michel, M.C. (2014) Cardiovascular and Ocular Safety of α1-Adrenoceptor Antagonists in the Treatment of Male Lower Urinary Tract Symptoms. Expert Opinion on Drug Safety, 13, 1187-1197.
<br>https://doi.org/10.1517/14740338.2014.936376Gul, A., Coban, S., Turkoglu, A.R., et al. (2020) Comparative Efficacy and Safety Profile of 4 vs 8 mg of Silodosin Once Daily Usage in Patients with Benign Prostatic Hyperplas-ia-Related Lower Urinary Tract Symptoms Divided into Subgroups According to International Prostate Symptom Score Severity. Prostate International, 8, 152-157.
<br>https://doi.org/10.1016/j.prnil.2020.04.002王志嵩, 李庆元. 非那雄胺治疗良性前列腺增生症临床分析[J]. 人人健康, 2019(24): 13.段刘剑, 钱苏波. 前列腺增生患者应用非那雄胺治疗前后前列腺移行带体积变化的临床意义[J]. 现代泌尿外科杂志, 2021, 26(10): 831-835.彭昊. 非那雄胺、坦索罗辛和特拉唑嗪治疗良性前列腺增生症的疗效比较[J]. 中国实用医药, 2017, 12(21): 111-113.Nizov, A.N. (2019) Efficacy of 5-Reductase Inhibitors in the Treatment of Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia. Urologiia (Moscow, Russia: 1999), 5, 156-160.
<br>https://doi.org/10.18565/urology.2019.5.156-160Traish, A.M. (2020) Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It’s Time to Sound the Alarm. World Journal of Men’s Health, 38, 323-337. <br>https://doi.org/10.5534/wjmh.200012Van Kerrebroeck, P., Kreder, K., Jonas, U., et al. (2001) Tolterodine Once-Daily: Superior Efficacy and Tolerability in the Treatment of the Overactive Bladder. Urology, 57, 414-421. <br>https://doi.org/10.1016/S0090-4295(00)01113-4Mónica, F.Z. and De Nucci, G. (2019) Tadalafil for the Treatment of Benign Prostatic Hyperplasia. Expert Opinion on Pharmacotherapy, 20, 929-937. <br>https://doi.org/10.1080/14656566.2019.1589452Ückert, S., Richter, K., Fischer, K.-D., Tsikas, D. and Kuczyk, M.A. (2021) Re-Evaluation of the Immunohistochemical Distribution of Isoforms of Nitric Oxide Synthase in the Human Prostate: A Light and Electron Microscopical Study. Andrologia, 53, e14098. <br>https://doi.org/10.1080/14656566.2019.1589452Shimizu, S., Nagao, Y., Kataoka, T., et al. (2020) Protective Effects of Tadalafil on Prostatic Hyperplasia in Spontaneously Hypertensive Rats. European Journal of Pharmacology, 882, Article ID: 173313.
<br>https://doi.org/10.1016/j.ejphar.2020.173313Yamaguchi, O. (2013) Latest Treatment for Lower Urinary Tract Dysfunction: Therapeutic Agents and Mechanism of Action. International Journal of Urology, 20, 28-39. <br>https://doi.org/10.1111/iju.12008Coelho, A., Antunes-Lopes, T., Gillespie, J. and Cruz, F. (2017) Beta-3 Ad-renergic Receptor Is Expressed in Acetylcholine-Containing Nerve Fibers of the Human Urinary Bladder: An Immuno-histochemical Study. Neurourology and Urodynamics, 36, 1972-1980. <br>https://doi.org/10.1002/nau.23224Keam, S.J. (2018) Vibegron: First Global Approval. Drugs, 78, 1835-1839.
<br>https://doi.org/10.1007/s40265-018-1006-3Gleicher, S., Sebesta, E.M., Reynolds, W.S., Reynolds, S. and Dmochowski, R. (2022) Vibegron for the Treatment of Overactive Bladder: A Comprehensive Update. Expert Opinion on Pharmacotherapy, 23, 1479-1484.
<br>https://doi.org/10.1080/14656566.2022.2126311Nickel, J.C., Gilling, P., Tammela, T.L., et al. (2011) Com-parison of Dutasteride and Finasteride for Treating Benign Prostatic Hyperplasia: The Enlarged Prostate International Comparator Study (EPICS). BJU international, 108, 388-394.
<br>https://doi.org/10.1111/j.1464-410X.2011.10195.xFong, Y.K., Milani, S. and Djavan, B. (2005) Role of Phytotherapy in Men with Lower Urinary Tract Symptoms. Current Opinion in Urology, 15, 45-48. <br>https://doi.org/10.1097/00042307-200501000-00011Ye, Z., Huang, J., Zhou, L., et al. (2019) Efficacy and Safety of Serenoa repens Extract among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Random-ized, Double-Blind, Placebo-Controlled Trial. Urology, 129, 172-179. <br>https://doi.org/10.1016/j.urology.2019.02.030于文晓. 良性前列腺增生症中西医结合多学科诊疗指南(2022版) [J]. 中国男科学杂志, 2022, 36(2): 96-102.孙自学, 宋春生, 邢俊平, 等. 良性前列腺增生中西医结合诊疗指南(试行版) [J]. 中华男科学杂志, 2017, 23(3): 280-285.李东. 王琦教授治疗良性前列腺增生的经验[J]. 中华中医药杂志, 2011, 26(2): 286-288.徐桂兴, 罗廖君, 银子涵, 等. 基于数据挖掘近10年针灸治疗良性前列腺增生症用穴规律研究[J]. 世界科学技术-中医药现代化, 2020, 22(4): 1330-1340.